Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.51B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$985M |
| 3 |
Apple
AAPL
|
+$890M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$774M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$736M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$673M |
| 2 |
Bank of America
BAC
|
+$615M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$515M |
| 4 |
NVIDIA
NVDA
|
+$451M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$417M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.95% |
| 2 | Financials | 8.18% |
| 3 | Consumer Discretionary | 7.81% |
| 4 | Healthcare | 7.12% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4401
Shell
SHEL
$248B
| $149K | ﹤0.01% |
2,265
-402,727
| -99% | -$26.4M |
|
|
TGAN
4402
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $148K | ﹤0.01% |
40,519
+35,006
| +635% | +$95.9K |
|
4403
TELA Bio
TELA
$38.5M
| $147K | ﹤0.01% |
22,270
+19,341
| +660% | +$112K |
|
4404
Vanguard Morningstar Mid-Cap Growth ETF
VOT
$19.6B
| $147K | ﹤0.01% |
670
| – | – |
|
4405
Cue Biopharma
CUE
$113M
| $147K | ﹤0.01% |
1,851
+1,451
| +363% | +$104K |
|
|
SII
4406
Sprott
SII
$2.89B
| $145K | ﹤0.01% |
4,281
-35
| -0.8% | -$1.08K |
|
4407
Neuropace
NPCE
$474M
| $144K | ﹤0.01% |
13,971
+3,132
| +29% | +$25K |
|
4408
ESS Tech
GWH
$19.8M
| $143K | ﹤0.01% |
8,367
+7,342
| +716% | +$149K |
|
|
MITT
4409
TPG Mortgage Investment Trust
MITT
$222M
| $143K | ﹤0.01% |
22,507
+6,940
| +45% | +$37.7K |
|
4410
LanzaTech
LNZA
$68M
| $143K | ﹤0.01% |
283
+193
| +214% | +$84.9K |
|
|
OMGA
4411
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $141K | ﹤0.01% |
46,973
+29,013
| +162% | +$58.8K |
|
4412
DLH Holdings
DLHC
$70.4M
| $140K | ﹤0.01% |
8,881
+6,837
| +334% | +$96K |
|
4413
Latham Group
SWIM
$849M
| $140K | ﹤0.01% |
53,176
+46,673
| +718% | +$116K |
|
|
CCRD
4414
DELISTED
CoreCard
CCRD
| $139K | ﹤0.01% |
+10,076
| New | +$169K |
|
4415
SKYX Platforms
SKYX
$160M
| $139K | ﹤0.01% |
86,879
+75,037
| +634% | +$117K |
|
|
ASRT
4416
DELISTED
Assertio
ASRT
| $138K | ﹤0.01% |
8,605
+7,072
| +461% | +$175K |
|
4417
Cartesian Therapeutics
RNAC
$265M
| $138K | ﹤0.01% |
6,672
+4,683
| +235% | +$140K |
|
4418
Rallybio
RLYB
$85.9M
| $137K | ﹤0.01% |
7,185
+6,416
| +834% | +$157K |
|
4419
MediciNova
MNOV
$66.9M
| $137K | ﹤0.01% |
91,300
-12,500
| -12% | -$22.6K |
|
|
NGMS
4420
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $137K | ﹤0.01% |
4,780
-48
| -1% | -$1.3K |
|
4421
Caesarstone
CSTE
$76.1M
| $134K | ﹤0.01% |
35,935
+13,344
| +59% | +$53.8K |
|
|
ORGN
4422
DELISTED
Origin Materials
ORGN
| $134K | ﹤0.01% |
5,354
+3,964
| +285% | +$114K |
|
|
FREE
4423
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
| $134K | ﹤0.01% |
39,224
+37,145
| +1,787% | +$125K |
|
4424
GoodRx Holdings
GDRX
$1.27B
| $133K | ﹤0.01% |
19,911
+1,051
| +6% | +$5.92K |
|
4425
Eagle Bancorp Montana
EBMT
$191M
| $133K | ﹤0.01% |
8,402
| – | – |
|
Similar funds
Barclays's Q4 2023 Portfolio in Review
As of Q4 2023, Barclays held 5,469 positions worth $273B, up 70% from $161B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Barclays deployed $85.1B of net new capital in Q4 2023, opening 898 new positions and adding to 2,915 existing holdings. Its largest new stake was AngloGold Ashanti: 9,667,894 shares worth $181M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 27% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $673M trimmed.
- Barclays's largest Q4 2023 buy was AngloGold Ashanti: 9,667,894 shares worth $181M.
- Barclays added most to Meta Platforms (Facebook) in Q4 2023, an estimated $1.51B increase.
- Barclays's biggest Q4 2023 reduction was CRH, cutting an estimated $673M.
- Barclays fully exited Activision Blizzard in Q4 2023, selling an estimated $417M.
- Barclays's ten largest holdings make up 27% of its $273B portfolio in Q4 2023.
- Barclays opened 898 new positions and closed 253 in Q4 2023.
- Barclays's portfolio value rose 70% quarter-over-quarter to $273B.
Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.